Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Hematology

The Bone Marrow Connection: PNH, Aplastic Anemia, and MDS

At a Glance

PNH frequently occurs alongside bone marrow conditions like Aplastic Anemia and MDS. This happens because PNH cells can survive the immune system attacks that cause Aplastic Anemia. If you have both, treatment usually focuses on fixing the underlying bone marrow failure first.

It is very common for Paroxysmal Nocturnal Hemoglobinuria (PNH) to be diagnosed alongside other bone marrow conditions. In fact, PNH is often called a “sister disease” to Aplastic Anemia (AA) and Myelodysplastic Syndromes (MDS) [1][2]. Understanding this connection can help you make sense of why your doctor may be monitoring your blood counts so closely.

The Two Faces of PNH

Doctors generally divide PNH into two main categories based on how the disease behaves:

  1. Classic PNH: In this version, your bone marrow is healthy and producing plenty of cells, but many of them are PNH cells. The main problems are hemolysis (the destruction of red blood cells) and the risk of thrombosis (blood clots) [3][4].
  2. PNH with Bone Marrow Failure: In this version, your bone marrow is “failing” and not making enough of any kind of blood cell (red cells, white cells, or platelets). You might have a PNH clone, but the bigger issue is the overall lack of blood cells, which can lead to infections or bleeding [1][5].

The “Immune Escape” Theory

You might wonder why a PNH mutation would appear in a patient who already has Aplastic Anemia. Scientists believe this happens because of a process called immune escape [6].

In Aplastic Anemia, your immune system mistakenly attacks your own healthy bone marrow stem cells. However, PNH cells (because they are missing certain proteins on their surface) are effectively “invisible” to this specific immune attack [7][8]. This gives the PNH cells a survival advantage—while the healthy cells are being destroyed by the immune system, the PNH cells are “escaping” the attack and growing in number [6][9].

How the Connection Changes Your Treatment

The presence of bone marrow failure changes how your medical team will approach your care:

  • Treating the Failure First: If your blood counts are dangerously low due to Aplastic Anemia, the priority is often to fix the bone marrow. This may involve Immunosuppressive Therapy (IST) to stop the immune attack or even a Bone Marrow Transplant (also called a Stem Cell Transplant) to replace the failing marrow with healthy cells [10][11].
  • Managing Hemolysis: If you also have symptoms of hemolysis (like dark urine or severe fatigue), your doctor may add a complement inhibitor (like eculizumab) to protect your red blood cells while the other treatments work on the bone marrow [12][13].
  • A “Silver Lining”: Interestingly, having a small PNH clone when you are diagnosed with Aplastic Anemia is often seen as a positive sign. It can suggest that your Aplastic Anemia is immune-related and may respond better to immunosuppressive treatments [14][15].

Monitoring for Changes

Because these conditions are related, your doctor will perform regular blood tests and occasional bone marrow biopsies. This is to ensure that the disease isn’t “evolving” into something else, such as MDS (where the bone marrow makes poorly formed cells) or, very rarely, leukemia [2][16]. Early detection of these changes is key to adjusting your treatment plan effectively.

Common questions in this guide

What is the difference between classic PNH and PNH with bone marrow failure?
In classic PNH, your bone marrow produces enough cells, but red blood cells are actively destroyed (hemolysis) and blood clots can occur. In PNH with bone marrow failure, your marrow stops making enough healthy red cells, white cells, or platelets, which can lead to frequent infections or excessive bleeding.
Why do PNH and Aplastic Anemia often happen together?
PNH and Aplastic Anemia are linked through a process called immune escape. In Aplastic Anemia, the immune system mistakenly attacks healthy bone marrow, but PNH cells are missing certain surface proteins that make them invisible to this attack, allowing them to survive and multiply.
If I have both PNH and Aplastic Anemia, which condition is treated first?
Treatment priority depends on your specific symptoms and blood counts. If bone marrow failure is severely lowering your blood counts, doctors usually prioritize treating the Aplastic Anemia first using immunosuppressive therapy or a stem cell transplant.
How does having a PNH clone affect my Aplastic Anemia prognosis?
Having a small PNH clone when you are diagnosed with Aplastic Anemia can actually be a positive sign. It suggests your Aplastic Anemia is driven by the immune system, meaning it may respond better to immunosuppressive treatments.
Will my PNH or Aplastic Anemia turn into something more serious?
While these conditions require close monitoring, there is a risk they could evolve into other bone marrow disorders like Myelodysplastic Syndromes (MDS) or, very rarely, leukemia. Your medical team will perform regular blood tests and bone marrow biopsies to catch any changes early and adjust your treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do I have 'Classic PNH' or is my PNH clone related to another condition like Aplastic Anemia or MDS?
  2. 2.Is my main problem right now the destruction of red blood cells (hemolysis) or is it that my bone marrow isn't making enough blood cells (bone marrow failure)?
  3. 3.If I have both PNH and Aplastic Anemia, which one should we treat first?
  4. 4.What is the risk that my condition could change into something more serious, like Myelodysplastic Syndrome (MDS)?
  5. 5.How often do I need a bone marrow biopsy to check for changes in my bone marrow's health?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Evolution patterns of paroxysmal nocturnal hemoglobinuria clone and clinical implications in acquired bone marrow failure.

    Lian Y, Shi J, Nie N, et al.

    Experimental hematology 2019; (77()):41-50 doi:10.1016/j.exphem.2019.08.005.

    PMID: 31472171
  2. 2

    Origins of myelodysplastic syndromes after aplastic anemia.

    Negoro E, Nagata Y, Clemente MJ, et al.

    Blood 2017; (130(17)):1953-1957 doi:10.1182/blood-2017-02-767731.

    PMID: 28893734
  3. 3

    Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology.

    Bektas M, Copley-Merriman C, Khan S, et al.

    Journal of managed care & specialty pharmacy 2020; (26(12-b Suppl)):S3-S8 doi:10.18553/jmcp.2020.26.12-b.s3.

    PMID: 33356782
  4. 4

    Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers.

    Vallet N, de Fontbrune FS, Loschi M, et al.

    Haematologica 2018; (103(3)):e103-e105 doi:10.3324/haematol.2017.182360.

    PMID: 29269526
  5. 5

    Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry.

    Kim JS, Jang JH, Yoon SS, et al.

    Annals of hematology 2016; (95(1)):125-133 doi:10.1007/s00277-015-2511-z.

    PMID: 26416513
  6. 6

    Clonal expansion mechanisms in paroxysmal nocturnal hemoglobinuria.

    Kinoshita T

    International journal of hematology 2026; doi:10.1007/s12185-026-04167-5.

    PMID: 41656394
  7. 7

    Aplastic anemia: Pathophysiology.

    Giudice V, Selleri C

    Seminars in hematology 2022; (59(1)):13-20 doi:10.1053/j.seminhematol.2021.12.002.

    PMID: 35491054
  8. 8

    Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15.

    Tsuji N, Hosokawa K, Urushihara R, et al.

    Leukemia 2022; (36(6)):1666-1675 doi:10.1038/s41375-022-01549-6.

    PMID: 35474098
  9. 9

    Immunological links between aplastic anemia and paroxysmal nocturnal hemoglobinuria.

    Hosokawa K

    International journal of hematology 2026; doi:10.1007/s12185-026-04236-9.

    PMID: 42260206
  10. 10

    Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice-frequency and indications.

    Wong SA, Dalal BI, Leitch HA

    Current oncology (Toronto, Ont.) 2018; (25(5)):e391-e397 doi:10.3747/co.25.4018.

    PMID: 30464689
  11. 11

    Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Aplastic Anemia: A Multicenter Turkish Experience

    Yılmaz F, Soyer N, Cengiz Seval G, et al.

    Turkish journal of haematology : official journal of Turkish Society of Haematology 2021; (38(3)):195-203 doi:10.4274/tjh.galenos.2021.2021.0105.

    PMID: 34057336
  12. 12

    Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis.

    Pagliuca S, Risitano AM, De Fontbrune FS, et al.

    Bone marrow transplantation 2018; (53(1)):105-107 doi:10.1038/bmt.2017.220.

    PMID: 29131151
  13. 13

    Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort.

    Choi CW, Jang JH, Kim JS, et al.

    Blood research 2017; (52(3)):207-211 doi:10.5045/br.2017.52.3.207.

    PMID: 29043236
  14. 14

    The predictive value of pre-treatment paroxysmal nocturnal hemoglobinuria clone on response to immunosuppressive therapy in patients with aplastic anemia: a meta-analysis.

    Wang B, He B, Zhu YD, Wu W

    Hematology (Amsterdam, Netherlands) 2020; (25(1)):464-472 doi:10.1080/16078454.2020.1848083.

    PMID: 33269994
  15. 15

    The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

    Stahl M, DeVeaux M, de Witte T, et al.

    Blood advances 2018; (2(14)):1765-1772 doi:10.1182/bloodadvances.2018019414.

    PMID: 30037803
  16. 16

    Significance of paroxysmal nocturnal hemoglobinuria clone in immunosuppressive therapy for children with severe aplastic anemia.

    Li J, Zong SY, Yin ZX, et al.

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2022; (24(3)):303-308 doi:10.7499/j.issn.1008-8830.2110109.

    PMID: 35351262

This page provides educational information about the relationship between PNH, Aplastic Anemia, and MDS. It is not intended to replace professional medical advice from your hematologist or oncologist.

Get notified when new evidence is published on Paroxysmal nocturnal hemoglobinuria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.